Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Insider David Krempa Sells 6,800 Shares

Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Get Free Report) insider David Krempa sold 6,800 shares of the firm's stock in a transaction on Friday, June 13th. The shares were sold at an average price of $14.77, for a total transaction of $100,436.00. Following the completion of the transaction, the insider now directly owns 622,869 shares in the company, valued at approximately $9,199,775.13. This represents a 1.08% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

David Krempa also recently made the following trade(s):

• On Monday, June 16th, David Krempa sold 10,223 shares of Eton Pharmaceuticals stock. The shares were sold at an average price of $14.73, for a total value of $150,584.79.
• On Thursday, June 12th, David Krempa sold 16,977 shares of Eton Pharmaceuticals stock. The stock was sold at an average price of $14.92, for a total transaction of $253,296.84.

Eton Pharmaceuticals Trading Down 0.9%

NASDAQ:ETON traded down $0.13 during mid-day trading on Monday, reaching $14.17. 324,095 shares of the stock were exchanged, compared to its average volume of 224,421. Eton Pharmaceuticals, Inc. has a 1-year low of $3.18 and a 1-year high of $21.48. The firm has a market capitalization of $380.01 million, a PE ratio of -64.41 and a beta of 1.28. The business has a fifty day moving average price of $16.54 and a 200 day moving average price of $15.05.

Eton Pharmaceuticals (NASDAQ:ETON - Get Free Report) last issued its quarterly earnings results on Tuesday, May 13th. The company reported $0.07 earnings per share for the quarter, missing analysts' consensus estimates of $0.09 by ($0.02). The company had revenue of $17.28 million during the quarter, compared to analysts' expectations of $14.33 million. Eton Pharmaceuticals had a negative return on equity of 36.29% and a negative net margin of 15.81%. On average, sell-side analysts forecast that Eton Pharmaceuticals, Inc. will post -0.14 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Two Sigma Advisers LP acquired a new position in Eton Pharmaceuticals in the 4th quarter valued at approximately $662,000. Millennium Management LLC bought a new stake in Eton Pharmaceuticals during the fourth quarter worth approximately $1,850,000. Balyasny Asset Management L.P. bought a new stake in shares of Eton Pharmaceuticals during the 4th quarter worth $158,000. Two Sigma Investments LP bought a new position in shares of Eton Pharmaceuticals in the fourth quarter worth about $1,498,000. Finally, Jane Street Group LLC grew its stake in shares of Eton Pharmaceuticals by 328.6% in the fourth quarter. Jane Street Group LLC now owns 64,323 shares of the company's stock worth $857,000 after acquiring an additional 49,317 shares during the last quarter. 27.86% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the company. HC Wainwright reiterated a "buy" rating and set a $35.00 target price (up from $33.00) on shares of Eton Pharmaceuticals in a research note on Thursday, May 29th. B. Riley restated a "buy" rating and set a $26.00 price objective (up previously from $24.00) on shares of Eton Pharmaceuticals in a research report on Friday, May 16th. Finally, Craig Hallum lifted their price target on Eton Pharmaceuticals from $26.00 to $28.00 and gave the company a "buy" rating in a report on Wednesday, May 14th.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.